Small Business Innovation Research (SBIR)
The Small Business Innovation Research (SBIR) program is a set-aside program (3.2% of an agency's extramural budget in FY2017) for domestic small business concerns to engage in Research/Research and Development (R/R&D) that has the potential for commercialization and public benefit. The SBIR program was established under the Small Business Innovation Development Act of 1982 (P.L. 97-219).
CDC’S Small Business Innovation Research (SBIR) program functions to promote Research and Development (R&D) from small businesses, where innovation and innovators thrive, in order to effectively support the health promotion and disease prevention needs and goals of CDC.
Today, CDC’s SBIR program is under the stewardship of the Office of the Associate Director for Science, Office of Technology and Innovation (OTI). This office is committed to ensuring a competitive award process that results in projects of scientific excellence and technological innovation with the potential for commercialization.
About the SBIR Program
The SBIR Program was established by Congress to provide increased opportunities for small businesses to participate in R&D, to increase employment, and to improve U.S. competitiveness.
The program's specific objectives are to:
- Use small businesses to stimulate technological innovation
- Strengthen the role of small business in meeting Federal R/R&D needs
- Increase private sector commercialization of innovations developed through Federal SBIR R&D
- Increase small business participation in Federal R/R&D
- Foster and encourage participation by socially and economically disadvantaged small business concerns and women-owned business concerns in the SBIR program
Only United States small business concerns (SBCs) are eligible to submit SBIR applications. A SBC is one that, on the date of award for both Phase I and Phase II funding agreements, meets ALL of the criteria as described in the current SBIR parent funding opportunity announcement available at the NIH Small Business Funding Opportunities website.
Three Phases of SBIR
Funding is awarded competitively and is available for only Phases I and II of the SBIR program:
- Phase I awards projects up to $150,000 for approximately 6 months to support exploration of the technical merit or feasibility of an idea or technology.
- Phase II awards projects that expand Phase I results. Awards are for up to $1,000,000 for a time period of up to 2 years. During this time, the R&D work is performed and the developer evaluates commercialization potential.
- Phase III is the period during which Phase II innovation moves from the laboratory into the marketplace. At this stage, the small business must find funding in the private sector or other non-SBIR funding.
CDC SBIR Funding Opportunities
- CDC participates in the PHS 2016-2 SBIR Omnibus FOA (PA-16-302 ) Grant Solicitation with NIH, FDA, and ACF. The first submission date was September 6, 2016. The next submission dates are on January 5, 2017, and April 5, 2017.
- CDC participated along with NIH in the PHS 2017-1 SBIR Contract Solicitation. The SBIR Contract Solicitation is currently closed. All CDC SBIR Contract proposals were due October 21, 2016 by 5:00PM EDT. Contracts proposals were submitted electronically using the NIH/NIAID Contract Proposal Submission (eCPS) website.
For a list of CDC funded SBIR contracts and grants from FY2013 to FY2015, please see: CDC SBIR Phase I and Phase II Awardees FY2013-FY2015.
For more information about individual funded projects, visit the NIH RePORTER.
SBIR Report Fraud, Waste, and Abuse
The Office of Inspector General (OIG) promotes the effective, efficient, and economical operation of Department of Health & Human Services programs and operations through audits, inspections, investigations, and other reviews.The HHS OIG Hotline accepts tips from all sources about potential fraud, waste, abuse, and mismanagement in Department of Health & Human Services programs. The reporting individual should indicate the fraud, waste, and/or abuse concerns for a SBIR grant or contract, if relevant.
Visit the OIG Report Fraud website for additional information.
Please direct all inquiries to: Office of Technology and Innovation, firstname.lastname@example.org, 404-718-1386.
- Page last reviewed: January 3, 2017
- Page last updated: January 31, 2017
- Content source:
- Office of the Associate Director for Science